Elezanumab
Based on 1 Customer Validation
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.91%
- CAS. Nr.: 1791416-49-3
- Molecular Weight:146.44 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgG1 lambda2
Human
RGMA
Elezanumab (0.01, 0.1, 1, 10 mg/kg; IV; once a week for 3 doses ) promotes axonal regeneration and remyelination, decreases inflammatory lesion area and improves functional recovery in the spinal targeted experimental autoimmune encephalomyelitis (EAE) model (female Lewis rats)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Lewis rat optic neuritis models[1]
-
Dosage:1, 3, or 10 mg/kg
-
Administration:IV; once a week for 5 doses
-
Result:Protected against the optic nerve inflammationinduced RNFL degeneration.
Showed significant protection of the RNFL, as demonstrated by decreased reduction in RNFL thickness measured by optical coherence tomography (OCT) with 10 mg/kg
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda2
ELISA, FACS, Functional assay
-
Immobilized Human RGMA Protein (His Tag) can bind Elezanumab. The EC50 for this effect is 2.09 ng/mL.
Chemical Information
-
CAS. Nr. 1791416-49-3
-
Appearance Liquid
-
Molecular Weight 146.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Elezanumab]
-
Synonyms
ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Lili Huang, et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. Neurobiol Dis. 2021 Nov;159:105492. [Content Brief]
[2]. Peer B Jacobson, et al. Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates. Neurobiol Dis. 2021 Jul;155:105385. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Elezanumab Related Classifications
HY-P99359 Related Classifications
Powered by Bioz